Literature DB >> 24780461

New insights into the use of biomarkers of diabetic nephropathy.

Jay C Jha1, Karin A M Jandeleit-Dahm1, Mark E Cooper2.   

Abstract

Diabetic nephropathy (DN) is a major microvascular complication of diabetes characterized by increasing albuminuria and progressive loss of kidney function. Increased excretion of albumin into the urine is a key feature of DN, and its assessment is considered to be an early marker predicting the onset and progression of DN. However, albuminuria has certain limitations; therefore, the quest for more reliable renal biomarkers with higher sensitivity and specificity are needed for early prediction of the onset and monitoring of the progression of DN. Furthermore, such biomarkers may also provide a better insight into identifying the complex pathophysiological processes responsible for DN. This article aims to provide a comprehensive and critical review of the current literature on relevant biomarkers of kidney injury, including markers of renal fibrosis, inflammation, and oxidative stress, as well as addressing contemporary proteomic approaches.
Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarkers; Diabetes; Diabetic nephropathy; Metabolomics; Proteomics

Mesh:

Substances:

Year:  2014        PMID: 24780461     DOI: 10.1053/j.ackd.2014.03.008

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  9 in total

Review 1.  Metabolomics in diabetic complications.

Authors:  Laura A Filla; James L Edwards
Journal:  Mol Biosyst       Date:  2016-02-19

2.  Urinary small extracellular vesicles derived CCL21 mRNA as biomarker linked with pathogenesis for diabetic nephropathy.

Authors:  Ye Feng; Xin Zhong; Hai-Feng Ni; Cui Wang; Tao-Tao Tang; Li-Ting Wang; Kai-Yun Song; Ri-Ning Tang; Hong Liu; Bi-Cheng Liu; Lin-Li Lv
Journal:  J Transl Med       Date:  2021-08-17       Impact factor: 5.531

3.  Berberine improves kidney function in diabetic mice via AMPK activation.

Authors:  Long Zhao; Li-Na Sun; Hui-Bin Nie; Xue-Ling Wang; Guang-Ju Guan
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

4.  Does combined peroxisome proliferator-activated receptors-agonist and pravastatin therapy attenuate the onset of diabetes-induced experimental nephropathy?

Authors:  Hayam I Gad
Journal:  Saudi Med J       Date:  2014-11       Impact factor: 1.484

5.  Incidence, Development, and Prognosis of Diabetic Kidney Disease in China: Design and Methods.

Authors:  Yao-Zheng Yang; Jin-Wei Wang; Fang Wang; Yun-Tao Wu; Hai-Yan Zhao; Min Chen; Lu-Xia Zhang; Shou-Ling Wu; Ming-Hui Zha
Journal:  Chin Med J (Engl)       Date:  2017-01-20       Impact factor: 2.628

6.  Comprehensive metabolic profiling of chronic low-grade inflammation among generally healthy individuals.

Authors:  Maik Pietzner; Anne Kaul; Ann-Kristin Henning; Gabi Kastenmüller; Anna Artati; Markus M Lerch; Jerzy Adamski; Matthias Nauck; Nele Friedrich
Journal:  BMC Med       Date:  2017-11-30       Impact factor: 8.775

7.  Salivary and serum interleukin-17A and interleukin-18 levels in patients with type 2 diabetes mellitus with and without periodontitis.

Authors:  Suteera Techatanawat; Rudee Surarit; Kongthawat Chairatvit; Weerapan Khovidhunkit; Sittiruk Roytrakul; Supanee Thanakun; Hiroaki Kobayashi; Siribang-On Piboonniyom Khovidhunkit; Yuichi Izumi
Journal:  PLoS One       Date:  2020-02-13       Impact factor: 3.240

8.  Effect of hyperglycemia and rosiglitazone on renal and urinary neprilysin in db/db diabetic mice.

Authors:  Laale F Alawi; Sana E Emberesh; Brenda A Owuor; Harshita Chodavarapu; Rucha Fadnavis; Salim S El-Amouri; Khalid M Elased
Journal:  Physiol Rep       Date:  2020-02

9.  The GenoDiabMar Registry: A Collaborative Research Platform of Type 2 Diabetes Patients.

Authors:  Adriana Sierra; Sol Otero; Eva Rodríguez; Anna Faura; María Vera; Marta Riera; Vanesa Palau; Xavier Durán; Anna Costa-Garrido; Laia Sans; Eva Márquez; Vladimir Poposki; Josep Franch-Nadal; Xavier Mundet; Anna Oliveras; Marta Crespo; Julio Pascual; Clara Barrios
Journal:  J Clin Med       Date:  2022-03-05       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.